Rekvina Laboratories Board Approvals, Preferential Issue Statement, and Key Executive Appointment
Rekvina Laboratories Ltd · Others (Uncategorized) · 13 Nov 2026, 11:57 pm
Rekvina Laboratories Board Approvals, Preferential Issue Statement, and Key Executive Appointment Rekvina Laboratories approved its standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26, accompanied by limited review reports. The company reported zero deviation in the utilization of ₹46 lakh raised via a preferential issue on 12th Aug'26, allocated toward working capital (₹40 lakh) and general corporate purposes (₹6 lakh), with nil funds deployed as of 30th Sep'26. Additionally, the Board appointed Ms. Bhagyshree Manojbhai Kandoi as Company Secretary and Compliance Officer, effective 16th Nov'26.
Original exchange filing (PDF)
More announcements from Rekvina Laboratories Ltd
- Appointment of Ms. Bhagyshree as a company Secretary and Compliance Officer w.e.f. 16.11.2026. · 13 Nov 2026
- Financial Result for QTR2 · 13 Nov 2026
- Outcome of Board Meeting · 13 Nov 2026
- Rekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Financial Result for QTR2 · 13 Nov 2026
- Intimation regarding Temporary Shutdown of Manufacturing Facility for Renovation, Upgradation and Installation of an Additional Vial Manufacturing Line. · 27 Oct 2026
- Appointment of Mr. Subrata Samanta as a Chief Financial officer of the company with effect from 07.10.2026. · 08 Oct 2026
- AGM Voting Results along-with Scrutinizer Report on E-Voting · 30 Sept 2026
- Summary of Proceeding of Annual General Meeting · 29 Sept 2026
